Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: testing Medication for Generalized Anxiety Disorder

This study aims to measure the clinical how well it works and safety of electroacupuncture (EA) as an added on top of your current treatment treatment for generalized anxiety disorder (GAD). Participants in the clinical trial will be randomly assigned to an EA group, a sham EA group, or a waiting-list control group.

Official registry: https://clinicaltrials.gov/study/NCT07392645 · Lishu Gao · enrollment listed as 123

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Electroacupuncture (EA), Sham Electroacupuncture (SEA), or Medication. The registry lists allocation as randomized. This study aims to measure the clinical how well it works and safety of electroacupuncture (EA) as an added on top of your current treatment treatment for generalized anxiety disorder (GAD).

They plan to enroll about 123 people at Hangzhou. Taking part typically means taking a study drug (or dummy pill), a procedure as part of the study plus check-ins.

Official title (unrewritten)

Clinical Efficacy of Electroacupuncture for Generalized Anxiety Disorder and Its Central Mechanism Based on Neuroimaging Changes

Interventions: Electroacupuncture (EA), Sham Electroacupuncture (SEA), Medication

Primary outcome (registry wording): Effective rate of HAMA score reduction at Week 4

Who it is for (from inclusion criteria)

  • Ages 18 Years to 60 Years
  • Meet the DSM-5 diagnostic criteria for Generalized Anxiety Disorder (GAD)
  • the patient has been taking the same anxiolytic medication consistently for 2 weeks prior to enrollment
  • Right-handed（for MRI)
  • Aged 18-60 years, with at least primary school education

Public study contact (from the registry)

Lishu Gao

+86 13858015836

rodelo@sina.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseRichmond, Virginia
Not a traditional drug phase: Antioxidant for Peripheral Vascular Diseases

The purpose of this research study is to examine the role oxidants, substances produced in the blood that can damage blood vessel function, may play in blood vessel function in healthy individuals as well as individuals with mental health disorders (posttraumatic stress disorder (PTSD) and/or generalized anxiety disorder (GAD)).

NCT04916327 · Official ClinicalTrials.gov record · Virginia Commonwealth University

RecruitingNot a traditional drug phaseLos Angeles, California
Not a traditional drug phase: Deep Brain Stimulation for Fear

Anxiety disorders such as post-traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD) affect a large number of individuals with a significant portion of patients failing to improve with current treatments. this study wants to understand the brain mechanisms that produce fear and anxiety in humans.

NCT05120635 · Official ClinicalTrials.gov record · Duke University

FAQ about this NCT record

Is NCT07392645 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07392645?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07392645?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary